10x Genomics Inc - Ordinary Shares - Class A Aktie News

Begins commercial shipments of Xenium Cell Segmentation Kit to improve determination of cell boundaries Launches first Xenium application-focused panel optimized for immuno-oncology across all tissue types PLEASANTON, Calif., March 21, 2024 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, announced today the commercial availability of its Xenium mul...

The next generation of the company's leading single cell technology architecture, GEM-X, enables higher performance at larger scale and lower cost PLEASANTON, Calif. , March 13, 2024 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, announced today that it has started shipping the first two products powered by the GEM-X technology architecture, Chrom...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Vizgen announces the denial of 10x Genomics' petition for Inter Partes Review of the Vizgen-licensed patent asserted against 10x's Xenium Platform.

The U.S. spends approximately $450 billion every year treating rare diseases. Investing guru Cathie Wood says managing patients afflicted with these illnesses could cost $20 trillion over their lifetime.

Ark Invest bought shares of Roku, 10x Genomics, and Intellia Therapeutics on Monday. Roku has shed more than one-third of its value over the past two weeks after a series of unfortunate events.

PLEASANTON, Calif. , Feb. 20, 2024 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, today announced that members of its management team will participate in a fireside chat at the 44th Annual TD Cowen Health Care Conference on Tuesday, March 5, at 2:50 p.m.

10x Genomics, Inc. (TXG) Q4 2023 Earnings Call Transcript

Q4 2023 revenue growth of 18% and FY 2023 revenue growth of 20% over the corresponding periods of 2022 PLEASANTON, Calif. , Feb. 15, 2024 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, today reported financial results for the fourth quarter and full year ended December 31, 2023 and provided outlook for 2024.